Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases

被引:0
作者
Wendy Balestri
Ruchi Sharma
Victor A. da Silva
Bianca C. Bobotis
Annabel J. Curle
Vandana Kothakota
Farnoosh Kalantarnia
Maria V. Hangad
Mina Hoorfar
Joanne L. Jones
Marie-Ève Tremblay
Jehan J. El-Jawhari
Stephanie M. Willerth
Yvonne Reinwald
机构
[1] Nottingham Trent University,Department of Engineering, School of Science and Technology
[2] Nottingham Trent University,Medical Technologies Innovation Facility
[3] University of Victoria,Department of Mechanical Engineering
[4] University of Victoria,Division of Medical Sciences
[5] University of Victoria,Centre for Advanced Materials and Related Technology (CAMTEC)
[6] University of Cambridge,Department of Clinical Neurosciences
[7] Nottingham Trent University,Department of Biosciences, School of Science and Technology
[8] University of Victoria,Department of Chemistry
[9] Université Laval,Neurosciences Axis, Centre de Recherche du CHU de Québec
[10] Université Laval,Department of Molecular Medicine
[11] The University of British Columbia,Department of Biochemistry and Molecular Biology
[12] McGill University,Department of Neurology and Neurosurgery
[13] University of Victoria,Institute On Aging and Lifelong Health
[14] Mansoura University,Department of Clinical Pathology, Faculty of Medicine
[15] University of British Columbia,School of Biomedical Engineering
来源
Journal of Neuroinflammation | / 21卷
关键词
Neuroimmune system; Alzheimer’s disease; Parkinson’s disease; Inflammation; Neurodegenerative diseases; Modeling;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by the interaction of genetic, environmental, and familial factors. These diseases have distinct pathologies and symptoms that are linked to specific cell populations in the brain. Notably, the immune system has been implicated in both diseases, with a particular focus on the dysfunction of microglia, the brain’s resident immune cells, contributing to neuronal loss and exacerbating symptoms. Researchers use models of the neuroimmune system to gain a deeper understanding of the physiological and biological aspects of these neurodegenerative diseases and how they progress. Several in vitro and in vivo models, including 2D cultures and animal models, have been utilized. Recently, advancements have been made in optimizing these existing models and developing 3D models and organ-on-a-chip systems, holding tremendous promise in accurately mimicking the intricate intracellular environment. As a result, these models represent a crucial breakthrough in the transformation of current treatments for PD and AD by offering potential for conducting long-term disease-based modeling for therapeutic testing, reducing reliance on animal models, and significantly improving cell viability compared to conventional 2D models. The application of 3D and organ-on-a-chip models in neurodegenerative disease research marks a prosperous step forward, providing a more realistic representation of the complex interactions within the neuroimmune system. Ultimately, these refined models of the neuroimmune system aim to aid in the quest to combat and mitigate the impact of debilitating neuroimmune diseases on patients and their families.
引用
收藏
相关论文
共 992 条
[91]  
Bessler N(2020)Current and future treatments in Alzheimer disease: an update J Cent Nerv Syst Dis 29 133-325.e13
[92]  
Figler K(2018)Levodopa-induced dyskinesia: clinical features, incidence, and risk factors J Neural Transm 125 1-596
[93]  
Buchholz MB(2018)Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study Neurology 91 574-683
[94]  
Rios AC(2019)Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations CNS Drugs 33 1-694
[95]  
Malda J(2020)Trehalose against Alzheimer’s disease: insights into a potential therapy BioEssays 42 15-33618
[96]  
Fouke KE(2019)Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer’s disease Ann Clin Transl Neurol 6 3501-10798
[97]  
Wegman ME(2021)Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys Brain 144 2216-1958
[98]  
Weber SA(2022)Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: a case report Front Oncol 18 40-1871
[99]  
Brady EB(2021)Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer’s disease Alzheimer’s & Dementia 7 117-1281
[100]  
Román-Vendrell C(2021)A phase 1 study of AL002 in healthy volunteers Alzheimer’s & Dementia 17 1064-187